[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0114978A - Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares - Google Patents

Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares

Info

Publication number
BR0114978A
BR0114978A BR0114978-4A BR0114978A BR0114978A BR 0114978 A BR0114978 A BR 0114978A BR 0114978 A BR0114978 A BR 0114978A BR 0114978 A BR0114978 A BR 0114978A
Authority
BR
Brazil
Prior art keywords
metabolic
compositions
useful
methods
diseases
Prior art date
Application number
BR0114978-4A
Other languages
English (en)
Inventor
Michele F Browner
Marc Labelle
David L Ckark
Xiaolin Hao
Timothy D Cushing
Ronald C Hawley
Xiao He
Juan C Jaen
Sharada S Labadie
Marie-Louise Smith
Francisco X Talamas
Nigel P C Walker
Original Assignee
Tularik Inc
Hofmann La Roche Ag F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc, Hofmann La Roche Ag F filed Critical Tularik Inc
Publication of BR0114978A publication Critical patent/BR0114978A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

"COMPOSIçõES E MéTODOS QUE SãO úTEIS NO TRATAMENTO DE CONDIçõES OU DOENçAS INFLAMATóRIAS, METABóLICAS, E PROLIFERATIVAS CELULARES". São aqui fornecidos compostos, composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares. Em particular, a invenção fornece compostos que modulam a expressão e/ou função de proteínas envolvidas na inflamação, metabolismo, e proliferação celular. Os compostos em questão contêm anéis carbocíclicos ou heterocíclicos fundidos.
BR0114978-4A 2000-10-26 2001-10-23 Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares BR0114978A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24358100P 2000-10-26 2000-10-26
PCT/US2001/051403 WO2002041843A2 (en) 2000-10-26 2001-10-23 Antiinflammation agents

Publications (1)

Publication Number Publication Date
BR0114978A true BR0114978A (pt) 2004-04-20

Family

ID=22919310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114978-4A BR0114978A (pt) 2000-10-26 2001-10-23 Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares

Country Status (20)

Country Link
US (3) US6846834B2 (pt)
EP (1) EP1333834B1 (pt)
JP (1) JP4285602B2 (pt)
KR (1) KR20030064773A (pt)
CN (1) CN1503673A (pt)
AR (1) AR035499A1 (pt)
AT (1) ATE392898T1 (pt)
AU (2) AU3980602A (pt)
BR (1) BR0114978A (pt)
CA (1) CA2427284A1 (pt)
DE (1) DE60133758T2 (pt)
EA (1) EA200300508A1 (pt)
ES (1) ES2305125T3 (pt)
IL (1) IL155519A0 (pt)
MX (1) MXPA03003599A (pt)
NO (1) NO20031869L (pt)
NZ (1) NZ525474A (pt)
PL (1) PL366114A1 (pt)
WO (1) WO2002041843A2 (pt)
ZA (1) ZA200303203B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
JP4285602B2 (ja) 2000-10-26 2009-06-24 アムジェン インコーポレイテッド 抗炎症剤
CN1582284A (zh) * 2001-11-07 2005-02-16 霍夫曼-拉罗奇有限公司 氨基嘧啶类和吡啶类化合物
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
JP4364120B2 (ja) 2002-06-06 2009-11-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換３−アミノ−チエノ［２，３−ｂ］ピリジン−２−カルボン酸アミド化合物、その製造方法及び使用
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
CA2534127A1 (en) 2003-07-31 2005-02-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzothiophene compounds and uses thereof
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
CN101500606B (zh) 2005-06-24 2013-12-04 杜克大学 基于热反应生物聚合物的直接药物送递系统
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
KR20080021077A (ko) 2005-06-30 2008-03-06 스미스클라인 비참 코포레이션 화합물
EP1948187A4 (en) * 2005-11-18 2010-11-03 Glaxosmithkline Llc CHEMICAL COMPOUNDS
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
JP2009539865A (ja) 2006-06-06 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用
DE102007012794B3 (de) * 2007-03-16 2008-06-19 Novaled Ag Pyrido[3,2-h]chinazoline und/oder deren 5,6-Dihydroderivate, deren Herstellungsverfahren und diese enthaltendes dotiertes organisches Halbleitermaterial
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
WO2008150827A1 (en) * 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
WO2010038465A1 (ja) * 2008-10-02 2010-04-08 旭化成ファーマ株式会社 ８位置換イソキノリン誘導体及びその用途
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
KR20170048590A (ko) 2014-09-16 2017-05-08 셀젠 콴티셀 리서치, 인크. 히스톤 데메틸라아제 억제제
EP3445170A4 (en) * 2016-04-18 2019-11-20 New York University CHINOLINE COMPOUNDS AS RAGE ACTIVITY MODULATORS AND USES THEREOF
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
US20220274929A1 (en) * 2019-02-25 2022-09-01 The Regents Of The University Of California Thiosemicarbazone compounds and uses thereof
WO2024072870A1 (en) * 2022-09-28 2024-04-04 New York University Quinoline compounds as modulators of rage activity and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
JP2001526648A (ja) * 1997-04-22 2001-12-18 コセンシス・インコーポレイテッド 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US5843721A (en) * 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
JP4763949B2 (ja) 1999-06-23 2011-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換されたベンゾイミダゾール
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
DE60117835T2 (de) 2000-10-03 2006-10-19 Bristol-Myers Squibb Co. Amino- substituierte tetracyclische Verbindungen,die als entzündungshemmende Mittel nützlich sind, und diese enthaltende Arzneimittel
WO2002030423A1 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
WO2002030353A2 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
JP4285602B2 (ja) 2000-10-26 2009-06-24 アムジェン インコーポレイテッド 抗炎症剤
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
WO2002060386A2 (en) 2001-02-01 2002-08-08 Bristol-Myers Squibb Company METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
US20020161004A1 (en) 2002-10-31
DE60133758T2 (de) 2009-07-02
ATE392898T1 (de) 2008-05-15
NZ525474A (en) 2005-10-28
MXPA03003599A (es) 2003-08-01
KR20030064773A (ko) 2003-08-02
AU2002239806B8 (en) 2002-06-03
WO2002041843A2 (en) 2002-05-30
US6846834B2 (en) 2005-01-25
IL155519A0 (en) 2003-11-23
EP1333834A4 (en) 2007-01-17
NO20031869L (no) 2003-06-26
PL366114A1 (en) 2005-01-24
JP4285602B2 (ja) 2009-06-24
ZA200303203B (en) 2004-04-26
US20050043330A1 (en) 2005-02-24
AR035499A1 (es) 2004-06-02
US7186841B2 (en) 2007-03-06
NO20031869D0 (no) 2003-04-25
CA2427284A1 (en) 2002-05-30
AU3980602A (en) 2002-06-03
DE60133758D1 (de) 2008-06-05
JP2004516252A (ja) 2004-06-03
EA200300508A1 (ru) 2004-06-24
US20070135464A1 (en) 2007-06-14
EP1333834B1 (en) 2008-04-23
CN1503673A (zh) 2004-06-09
AU2002239806B2 (en) 2007-01-18
EP1333834A2 (en) 2003-08-13
ES2305125T3 (es) 2008-11-01
WO2002041843A3 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
NO20061736L (no) Krystallform av epotilon B
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
EA199800667A1 (ru) Новые фенантридины
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE511840T1 (de) Imidazolderivate als entzündungshemmende mittel
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
BR0206985A (pt) Anticorpos modificados e métodos de uso
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1105144T1 (el) Χρηση μιας ουσιας που συνδεεται στον πepιφepειακο υποδοχεα των βενζοδιαζεπινων στη θepαπεια του δepματικου στρες
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
ATE128128T1 (de) Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.